Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 72 recruiting now early-phase tilt #69 of 28,707 conditions

Gastric Cancer: early-phase trial registry

72 of 159 indexed Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #69 of 28,707 conditions by registered trial count.

159 US clinical trials · 72 currently recruiting · #69 of 28,707 conditions by registered trial count

Gastric Cancer: 159 US clinical trials tracked, 72 recruiting.

Gastric Cancer is the subject of 159 registered US clinical trials on ClinicalTrials.gov, 72 of them currently open to new participants. 17 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.

Enrollment posture brief

Registry condition gastric-cancer

OPEN 72 | RECR 45% | LATE 17 | EARLY 118 | RANK #69 | SPON 11

Nearest open-share peer: Non-Small Cell Lung Cancer (45% recruiting · 455 trials)

Gastric Cancer (this)45%Obstructive Sleep Apnea42%Neoplasms31.3%Parkinson's Disease26.1%Influenza17.2%
Open-enrollment share among volume-matched conditions near Gastric Cancer

Gastric Cancer lists 72 open slots (45% of 159 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gastric Cancer is recruiting above its size-band peers.

    72 of 159 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Gastric Cancer trials is spread across many organizations.

    AstraZeneca accounts for 11 of 159 trials (6.9%). 107 distinct sponsors appear on at least one study for this condition label.

  3. Typical Gastric Cancer enrolment sits around 117 participants.

    Median target enrolment is 117 among the 154 trials that report a genuine target (sentinel values excluded). 65 of those (42.2%) plan for fewer than 100 participants.

  4. Gastric Cancer research is mostly interventional.

    142 interventional and 17 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 169Phase 249Phase 313Phase 44

Open and recent trials

159 total, page 4 of 4

COMPLETED Phase 1 22 participants

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

University of Southern California

NCT00183846

COMPLETED Phase 3 15 participants

Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial

National Cancer Institute (NCI)

NCT00941655

COMPLETED Phase 3 12 participants

Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma

Memorial Sloan Kettering Cancer Center

NCT01491698

COMPLETED Phase 2 12 participants

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

National Cancer Institute (NCI)

NCT04034251

COMPLETED Phase 2

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

SWOG Cancer Research Network

NCT00032123

COMPLETED Phase 2

BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Bristol-Myers Squibb

NCT00017043

COMPLETED Phase 2

T900607 in Treating Patients With Gastroesophageal Junction Cancer

University Hospitals Seidman Cancer Center

NCT00054249

COMPLETED Phase 2

DX-8951f in Treating Patients With Metastatic Stomach Cancer

Daiichi Sankyo

NCT00017212

COMPLETED Phase 2

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Radiation Therapy Oncology Group

NCT00009880

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 69
Phase 2 49
Phase 3 13
Phase 4 4

Named interventions

Most-linked intervention names on Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Paclitaxel Drug
10 trials
Pembrolizumab Drug
9 trials
Oxaliplatin Drug
8 trials
5-Fluorouracil Drug
7 trials
Nivolumab Drug
7 trials
Leucovorin Drug
7 trials
Capecitabine Drug
7 trials
fluorouracil Drug
5 trials

US sites by state

Facility locations filed on Gastric Cancer trials. A trial with sites in several states counts in each.

California 80 trials
Texas 59 trials
New York 46 trials
Florida 45 trials
Tennessee 29 trials
Michigan 28 trials
Massachusetts 28 trials
Pennsylvania 25 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gastric Cancer page

159 registered trials, 72 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 72 Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AstraZeneca sponsors the most Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastric Cancer condition card totals 159 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.